
AstraZeneca rejected the latest â€“ and supposedly final â€“ takeover offer from Pfizer.

British pharmaceutical company AstraZeneca once again has spurned U.S.-based Pfizer , which dubbed its latest $116 billion takeover offer "final."

CNBC reports AstraZeneca officials called the latest bid inadequate, saying it would create significant risks for the company's shareholders. AstraZeneca investors had mixed feelings about the rebuff, with some claiming the company could do better on price.

Pfizer has been pursuing its smaller British rival for months.

If you are commenting using a Facebook account, your profile information may be displayed with your comment depending on your privacy settings. By leaving the 'Post to Facebook' box selected, your comment will be published to your Facebook profile in addition to the space below.
